Company intelligence / Profile preview

Compass Therapeutics Advisors

Boston, Massachusetts, United States

Ownership: Private
Employees: ~32
Development stage: Other

Overview

Compass Therapeutics has advanced a pipeline of monoclonal and bispecific antibody drug candidates into clinical-stage development, with lead programs targeting major cancer pathways such as angiogenesis, tumor vascularization, and immune checkpoint inhibition. Clinical data has shown promising potential in modulating immune response in oncology settings.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodyBispecific monoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Compass Therapeutics Advisors.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Compass Therapeutics Advisors.

Explore the full profile